The Paralytic and the Steroid Are Both Still Running — Does Either Have to Be
Severe ARDS bought him days of neuromuscular blockade layered on stress-dose steroids for refractory shock. Both drugs did their job. The question now is whether the combination itself is quietly building the weakness that will keep him on the ventilator longest.
K.S., a 55-year-old man, developed severe ARDS after a complicated post-operative course following emergency bowel resection, now on hospital day nine — five of those days on continuous cisatracurium for refractory hypoxemia, overlapping with four days of stress-dose hydrocortisone for a period of vasopressor-dependent shock that has since resolved. His P/F ratio has improved enough that the team is weaning ventilator support, but a bedside exam this morning — the first time sedation has been light enough to genuinely test it — found him unable to lift either leg off the bed against gravity, an MRC sum score of 36 against the 48 below which ICU-acquired weakness is defined — not a borderline result he might test out of on a better day.
Combined exposure to neuromuscular blockade and corticosteroids has long been implicated as a specific driver of critical illness myopathy, historically traced back to reports from status asthmaticus patients receiving both drugs simultaneously decades before ICU-acquired weakness had its current name. The trial evidence on the neuromuscular-blocker side alone is genuinely mixed, though: ACURASYS, the trial most responsible for popularizing early paralysis in severe ARDS, measured ICU-acquired paresis directly and found no significant difference at all — 35.7 percent against 31.5 percent, p=0.51 — its authors concluding that early paralysis improved survival without increasing muscle weakness. ROSE, larger and later, arrived at the same place by a different route. Neither trial, in other words, indicts the paralytic. What neither one covers is the exposure K.S. actually received: ACURASYS capped cisatracurium at 48 hours, and he has had five days of it laid across four days of hydrocortisone. His nine-day course sits outside the window both trials studied, which is why their reassurance does not reach him and why the combined-exposure literature, not the blocker-alone trials, is the body of evidence that describes him.
His wife brings in a photo from four months earlier — K.S. finishing a half-marathon, visibly strong, nothing in the picture suggesting the man now unable to lift either leg against gravity is the same person. The contrast isn't sentimental framing for the team; it's a genuine clinical anchor, since distinguishing new ICU-acquired weakness from a pre-existing deconditioning baseline matters for how aggressively rehabilitation should be pursued and how confidently the team can counsel the family on expected recovery. Nothing in his history before this admission suggested any neuromuscular vulnerability at all.
At the bedside, ICU day 9
His P/F ratio is improving but he's not out of severe ARDS territory yet — I'd continue cisatracurium as long as his oxygenation genuinely requires it, titrated to the lowest effective train-of-four, rather than stopping early out of weakness concerns. Undertreating refractory hypoxemia has a faster, more certain cost than the weakness question does.
Agreed on continuing if oxygenation still needs it — but I'd focus specifically on the combined exposure, not treat the two drugs as independent risks running in parallel. Combined neuromuscular-blocker and corticosteroid exposure has long been the specifically implicated driver of critical illness myopathy, going back to reports in status asthmaticus patients on both drugs at once. The steroid is now off; the actual lever left is minimizing how much longer the paralytic overlaps with residual steroid effect, not accepting five more days as equally fixed.
Worth naming that the paralysis-drives-weakness story is less settled than the traditional teaching suggests. I want to correct a premise we're all half-carrying. ACURASYS didn't raise the weakness signal — it retired it: no difference in ICU-acquired paresis, 35.7 against 31.5 percent, and ROSE found the same. But neither trial licenses what we've actually done to him. ACURASYS paralyzed for 48 hours. He's at five days, over four days of steroid. He is outside the exposure both trials tested, so their reassurance doesn't transfer to him, and that cuts against your position rather than for it — it means we've been reading comfort from trials that never studied a course this long.
Agreed: cisatracurium continued but formally reassessed daily against oxygenation targets rather than left on the original order; hydrocortisone remained discontinued. Neuromuscular blockade was successfully stopped two days later once oxygenation no longer required it.
His weakness was formally diagnosed as ICU-acquired weakness on physical therapy evaluation and required an extended course of rehabilitation before hospital discharge — the team's chart note explicitly declined to attribute it definitively to either drug alone or their combination, consistent with the genuinely unsettled state of that specific causal question, while still documenting the overlap-duration limitation as the modifiable step taken going forward.